相关实验视频
Updated: Jun 29, 2025

Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
通过BCR信号和双击洞察力导航淋巴瘤:概述
Antonella Argentiero1, Alessandro Andriano2, Donatello Marziliano3
1Istituto Tumori "Giovanni Paolo II", Istituto di Ricovero e Cura a Carattere Scientifico, 70124 Bari, Italy.
非霍奇金淋巴瘤 (NHLs) 是淋巴细胞的各种癌症. 了解它们的遗传基础和像扩散型大B细胞淋巴瘤 (DLBCL) 这样的亚型,是开发向治疗的关键.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 非霍奇金淋巴瘤 (NHLs) 包含由B,T或NK淋巴细胞引起的多种淋巴增殖性疾病,占新确诊癌症的4-5%.
- 分类依赖于世卫组织的系统,整合了细胞系,形态,免疫类型和遗传学,分子分析提高了诊断准确性和预后标志物识别.
研究的目的:
- 审查非霍奇金淋巴瘤的分类,病原和不断发展的治疗策略.
- 突出分子变化的重要性,以了解NHL亚型和指导治疗决策.
主要方法:
- 关于NHL分类,分子机制和治疗进展的最新研究的文献综述.
- 对诊断方法的分析,包括白血病呈现的综合方法和活检材料的作用.
主要成果:
- 沉着的NHLs (例如,卵泡淋巴瘤,边缘区域淋巴瘤) 通常具有有利的预后.
- 侵袭性扩散性大B细胞淋巴瘤 (DLBCL) 是最常见的亚型,具有特定的遗传变异,如MYC转位和"双击"淋巴瘤 (MYC和BCL2/BCL6),表明预后不佳.
- 化学免疫疗法对于惰的NHLs是标准的,而强化疗法和向药物正在出现,用于攻击性或耐药性疾病.
结论:
- 对推动淋巴发育的遗传和微环境因素的持续研究对于NHL个性化治疗策略至关重要.
- 分子分析的进步对于完善NHL分类,识别预后标志物和开发新的向治疗至关重要.
更多相关视频
15:07VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
Published on: December 28, 2015
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
相关概念视频
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
The Intrinsic Apoptotic Pathway
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against...